AIM:ABC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£3.2b

Last Updated

2021/08/04 21:43 UTC

Data Sources

Company Financials +

Executive Summary

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Abcam's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABC is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ABC's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

7.1%

ABC

6.1%

GB Biotechs

1.6%

GB Market


1 Year Return

13.5%

ABC

37.3%

GB Biotechs

21.5%

GB Market

Return vs Industry: ABC underperformed the UK Biotechs industry which returned 37.3% over the past year.

Return vs Market: ABC underperformed the UK Market which returned 21.5% over the past year.


Shareholder returns

ABCIndustryMarket
7 Day7.1%6.1%1.6%
30 Day1.6%4.3%0.2%
90 Day-3.3%2.4%1.9%
1 Year13.5%13.5%37.7%37.3%26.8%21.5%
3 Year0.1%-1.9%27.9%26.0%13.9%1.4%
5 Year99.9%91.8%77.0%73.2%39.7%14.7%

Long-Term Price Volatility Vs. Market

How volatile is Abcam's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Abcam undervalued compared to its fair value and its price relative to the market?

4.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ABC (£14.23) is trading above our estimate of fair value (£12.58)

Significantly Below Fair Value: ABC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ABC is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ABC is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABC is good value based on its PB Ratio (5x) compared to the GB Biotechs industry average (5.6x).


Future Growth

How is Abcam forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

34.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: ABC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ABC's is expected to become profitable in the next 3 years.

Revenue vs Market: ABC's revenue (11.7% per year) is forecast to grow faster than the UK market (4.7% per year).

High Growth Revenue: ABC's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ABC's Return on Equity is forecast to be low in 3 years time (8%).


Past Performance

How has Abcam performed over the past 5 years?

-11.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABC is currently unprofitable.

Growing Profit Margin: ABC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABC is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.

Accelerating Growth: Unable to compare ABC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.8%).


Return on Equity

High ROE: ABC has a negative Return on Equity (-0.3%), as it is currently unprofitable.


Financial Health

How is Abcam's financial position?


Financial Position Analysis

Short Term Liabilities: ABC's short term assets (£307.5M) exceed its short term liabilities (£55.1M).

Long Term Liabilities: ABC's short term assets (£307.5M) exceed its long term liabilities (£138.0M).


Debt to Equity History and Analysis

Debt Level: ABC is debt free.

Reducing Debt: ABC had no debt 5 years ago.

Debt Coverage: ABC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ABC has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Abcam current dividend yield, its reliability and sustainability?

0.17%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ABC is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABC's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Alan Hirzel (53 yo)

6.92yrs

Tenure

UK£1,596,000

Compensation

Mr. Alan Thomas Hirzel, BS, MS, MBA, has been the Chief Executive Officer of Abcam Plc since September 8, 2014 and its Executive Director since January 30, 2014. Mr. Hirzel served as the Chief Marketing Of...


CEO Compensation Analysis

Compensation vs Market: Alan's total compensation ($USD2.22M) is above average for companies of similar size in the UK market ($USD1.68M).

Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ABC's management team is seasoned and experienced (5.6 years average tenure).


Board Members

Experienced Board: ABC's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Top Shareholders

Company Information

Abcam plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Abcam plc
  • Ticker: ABC
  • Exchange: AIM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£3.221b
  • Shares outstanding: 226.33m
  • Website: https://www.abcam.com

Number of Employees


Location

  • Abcam plc
  • Discovery Drive
  • Cambridge Biomedical Campus
  • Cambridge
  • Cambridgeshire
  • CB2 0AX
  • United Kingdom

Listings


Biography

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/04 21:43
End of Day Share Price2021/08/04 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.